Company intelligence / Profile preview

CellAegis Devices

Toronto, Ontario, Canadabroadviewventures.org ↗

Ownership: Private
Development stage: Other

Overview

CellAegis' autoRIC Device is CE marked and approved by Health Canada for use in acute care settings and at home, with ongoing large-scale clinical trials in the UK and Denmark. Data from meta-analyses suggest significant reduction in infarct size and heart failure/cardiac death among STEMI patients. US regulatory approval is pending following completion of pivotal trials[3][5].

Therapeutic areas: NephrologyCardiovascular
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

University College London / Hatter Cardiovascular Institute (ERIC-PPCI trial sponsor)[5]British Heart Foundation (funding partner for UK trial)[1][5]London School of Hygiene & Tropical Medicine (clinical trial management)[5]

Beyond the preview

Go deeper on CellAegis Devices.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellAegis Devices.

Explore the full profile